Esophageal Cancer Clinical Trials
Esophageal cancer clinical trials are constantly being conducted to test new therapies that have shown promise in preliminary studies. Through clinical trials, patients have access to treatments that aren’t yet available in other settings, and researchers have the opportunity to compare emerging therapies to the currently used options.
Every cancer treatment, even those that are currently considered the “gold standard” for treating esophageal cancer, was once only available through a clinical trial. Today’s trials are focused on exploring new options, such as:
- Novel chemotherapy drugs and combinations
- Advanced diagnostic techniques for early-stage cancers
- Innovative therapies such as electrocoagulation, immunotherapy, laser therapy and targeted genetic therapies
At Moffitt Cancer Center, we’re a recognized leader in esophageal cancer research. Moffitt is a National Cancer Institute-designated Comprehensive Cancer Center, and we have earned this designation through our commitment to investigative research. At any given time, we are conducting several different esophageal cancer studies, and we won’t conclude our efforts until there’s a proven cure.
When you come to Moffitt for esophageal cancer treatment, you can feel confident that you’re receiving the most advanced care possible – whether or not you choose to participate in a clinical trial. Our oncologists are extremely involved in the clinical trial process, and they take a bench-to-bedside approach, which means that they draw from their laboratory findings every time they create a patient’s care plan. This helps us give our patients the best possible chances of survival, while improving their overall quality of life.
Contact us for more information about our esophageal cancer clinical trials by calling 1-813-745-6100 or 1-800-679-0775 (toll-free) or submitting a clinical trials inquiry form online.
-
Clinical Trials
CLINICAL TRIAL 21589
BASECAMP-1: An Observational Study Obtaining Solid Tumor Tissue from Subjects with Primary Surgical Resection and Leukapheresis for CAR T-Cell Therapy Manufacturing
Condition: Immunotherapy
Intervention:
CLINICAL TRIAL 21742
Remote Resistance Exercise Powering Survivors- Gastrointestinal Oncology (Remote REPS-:GI)
Condition: Gastrointestinal Tumor
Intervention:
CLINICAL TRIAL 22685
Phase 1/1B, Multicenter, Open-Label, Study of RMC-9805 in Participants with Advanced KRASG12D-Mutant Solid Tumors
Condition: Multiple
Intervention: RMC-6236 (); RMC-9805 ()
CLINICAL TRIAL 23121
Exercise Prehabilitation for Locoregional Esophageal Cancer: A Pilot Study
Condition: Gastrointestinal Tumor
Intervention:
CLINICAL TRIAL 23230
Support through remote observation and nutrition guidance program for individuals with gastroesophageal cancer (STRONG-GEC)
Condition: Gastrointestinal Tumor
Intervention:
CLINICAL TRIAL 23480
A Phase 1/2 Study of a Selective FGFR2/3 Inhibitor, CGT4859, in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors Harboring FGFR2 and/or FGFR3 Genetic Alterations
Condition: Multiple
Intervention: CGT4859 ()
CLINICAL TRIAL 23549
A Phase 1/1b Study of VET3-TGI Administered Alone and in Combination with Atezolizumab in Patients with Advanced Solid Tumors
Condition: Thoracic
Intervention: Atezolizumab (Tecentriq); VET3-TGI ()
CLINICAL TRIAL 23660
A Phase 1 Study of MOMA-341 as Monotherapy or Combination Therapy in Participants with Advanced or Metastatic Solid Tumors
Condition: Multiple
Intervention:
CLINICAL TRIAL 23697
A Phase 1/1b, Open-label, Multicenter, First-in-human Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of VVD-159642, a RAS-PI3KA Inhibitor, as a Single Agent and in Combination in Participants With Advanced Solid Tumors
Condition: Multiple
Intervention: AMG 510 (Sotorasib); GSK1120212 (Trametinib); Olomorasib (); Sotorasib (); Trametinib (); VVD-159642 ()
CLINICAL TRIAL 23766
A First-in-Human Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of FID-022 as Monotherapy in Patients with Advanced Solid Tumors
Condition: Multiple
Intervention: FID-022 ()